SEC For		л			TEQ	2 61		ודום		EXC	спу			SSION					
FORM 4 UNITED STA					TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See					d purs	A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Randolph Sophia					A	2. Issuer Name and Ticker or Trading Symbol <u>ALX ONCOLOGY HOLDINGS INC</u> [ALXO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				ner	
(Last)(First)(Middle)C/O ALX ONCOLOGY HOLDINGS INC.866 MALCOLM ROAD, SUITE 100						3. Date of Earliest Transaction (Month/Day/Year) 07/16/2020								Chief Medical Officer					
(Street) BURLINGAME CA 94107				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	,	(Zip)																
1 Title of 9	Courity (Inc		ole I - Non	-Deriv			Curities		quired, D			f, or Bei		y Owned	at of	6.04	nership 7	. Nature	
1. Title of Security (Instr. 3) 2. Transa Date (Month/Da						Execution Date			, Transact Code (In	tion Di	on Disposed Of (D) (Instr.					Form (D) or	n: Direct of or Indirect I nstr. 4)	of Indirect Beneficial Ownership	
									Code	V A1	mount	t (A) or (D) Pr						(Instr. 4)	
		-	Table II - I (uired, Dis s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date, T	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		iration	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$ <u>19</u>	07/16/2020			A		89,657		(1)	07/16	.6/2030	Common Stock	89,657	\$0.00	89,65	57	D		

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020.

Remarks:

<u>/s/ Peter Garcia, by power of attorney</u>

07/17/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.